Previous 10 |
home / stock / anpcy / anpcy news
New CTC cluster researchpublished in prestigious nature publication f urther demonstrates theimportant role for Parsortix in enabling breakthrough developments in thetreatment of cancer. GUILDFORD, SURREY / ACCESSWIRE / February 11, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY),...
Interim Results for the six months ended 31 October 2018 ENROLMENT OF FDA BREAST CANCER STUDY 92% COMPLETE SAMPLE-TO-ANSWER SYSTEM (PARSORTIX-HYCEAD-ZIPLEX) DEVELOPED FOR NEW OVARIAN CANCER STUDY LEVERAGED PARTNERSHIP STRATEGY DIFFERENTIATES BUSINESS GUILDFORD, SUR...
Angle plc ("The Company") Customer Develops New Application for Parsortix System in Cancer Lymph Node Analysis Potential for Parsortix system to improve laboratory efficiency, reduce costs and improve medical decision-making and patient care GUILDFORD, ...
News, Short Squeeze, Breakout and More Instantly...
Angle Plc Surrey ADR Company Name:
ANPCY Stock Symbol:
OTCMKTS Market:
Angle Plc Surrey ADR Website:
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report a...
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analysis and ANGLE's DNA Damage Response assay GUILDFORD, SURREY / ACCESSWIRE / June 11, ...